| Autor: |
Gilda E. Ennis, Rebecca L. Koscik, Yue Ma, Erin M. Jonaitis, Carol A. Van Hulle, Tobey J. Betthauser, Allison M. Randall, Nathaniel Chin, Corinne D. Engelman, Rozalyn Anderson, Ivonne Suridjan, Gwendlyn Kollmorgen, Bradley T. Christian, Cynthia M. Carlsson, Sanjay Asthana, Sterling C. Johnson, Henrik Zetterberg, Kaj Blennow, Barbara B. Bendlin |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 13, Iss 1, Pp n/a-n/a (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2352-8729 |
| DOI: |
10.1002/dad2.12220 |
| Popis: |
Abstract Introduction We investigated whether insulin resistance (IR) was associated with longitudinal age‐related change in cognition and biomarkers of Alzheimer's disease (AD) pathology and neurodegeneration in middle‐aged and older adults who were non‐demented at baseline. Methods IR was measured with homeostatic model assessment of insulin resistance (HOMA2‐IR). Core AD‐related cerebrospinal fluid (CSF) biomarkers and cognition were assessed, respectively, on n = 212 (1 to 5 visits) and n = 1299 (1 to 6 visits). Linear mixed models tested whether HOMA2‐IR moderated age‐related change in CSF biomarkers and cognition. Linear regressions tested whether HOMA2‐IR x apolipoprotein E ε4 allele (APOE ε4) carrier status predicted amyloid beta [Aβ] chronicity (estimated duration of amyloid positron emission tomography [PET] positivity) (n = 253). Results Higher HOMA2‐IR was associated with greater cognitive decline but not with changes in CSF biomarkers. HOMA2‐IR x APOE4 was not related to Aβ chronicity but was significantly associated with CSF phosphorylated tau (P‐tau)181/Aβ42 level. Discussion In non‐demented adults IR may not be directly associated with age‐related change in AD biomarkers. Additional research is needed to determine mechanisms linking IR to cognitive decline. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text